General Session 4 (available abstracts)
Publication Number: GS4-03
Bernd Gerber, Angrit Stachs, Kristina Veselinovic, et al.
The authors conclude from the data that patients without SLNB benefited in terms of arm symptoms/function. There were no relevant differences in other QoL scales.
Publication Number: GS4-05
Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar one
Damiano Gentile, Wolfgang Gatzemeier, Erika Barbieri, et al.
The OS rate in the standard and experimental arm was over 99 percent; The DFS rate is 96.8% and 95.9% in the standard and experimental arms, respectively. After a median of 36 months, there was only one axillary relapse in the experimental arm. Seven distant relapses were observed in both arms and four and three deaths in the standard and experimental arms, respectively.
Publication Number: GS4-06
Marc D Ryser, Jane Lange, Lurdes Inoue, et al.
Overdiagnosis of screen-detected cancers is less common than in studies with excessive incidence estimates and more common than estimates in previous modeling studies that did not consider indolent tumors.
Publication Number: GS4-07
Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.
Genomic profiling in two independent DCIS cohorts with longitudinal section results provides different DCIS stroma expression patterns and immune cell compositions. RNA expression profiles provide information about the underlying tumor biology associated with later iBEs in both cohorts. In doing so, they gain new insights into DCIS biology and guide the development of diagnostic strategies to prevent invasive progression.
Publication Number: GS4-08
Anton Safonov, Chai Bandlamudi, Paulino Tallón de Lara, et al.
The analysis of germline-somatic interactions revealed new associations relevant to breast cancer progression and treatment resistance. BRCA2 carriers have worse results than the first-line CDK4 / 6i-ET. This has potential implications for optimal first-line therapy and sequencing of CDK4 / 6i versus PARPi in this patient population.
Publication Number: GS4-10
Komal Jhaveri, Haeseong Park, James Waisman, et al.
Neratinib + fulvestrant + trastuzumab (N+F+T ) is a promising combination for patients with HR +, HER2-mutant MBC with prior exposure to CDK4 / 6 inhibitors. Neratinib + trastuzumab also showed encouraging activity on HER2 mutant TNBC. The first results from the randomized comparison of N + F + T vs. F + T vs. F in patients with HR +, HER2-mutated MBC (Simon stage 1 analysis) will be presented at the conference.